Our programs are directed at treating metabolic diseases to minimize their long-term complications through end-organ protection.

PROGRAM
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PARTNER TERRITORY
Type 1 Diabetes
Dementia with Diabetes
Cystic Fibrosis Related Diabetes (CFRD)
Undisclosed
Partnered Programs
Type 2 Diabetes
Asia (*ROW retained)
Fatty Acid Oxidation Disorders
Worldwide
COPD
Asia (*ROW retained)